Sexually Transmitted Diseases Treatment Guidelines, 2015

Total Page:16

File Type:pdf, Size:1020Kb

Sexually Transmitted Diseases Treatment Guidelines, 2015 Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory Disease .......................................................................... 78 Mycoplasma genitalium ................................................................................ 20 Epididymitis .......................................................................................................... 82 HIV Infection: Detection, Counseling, and Referral ................................ 21 Human Papillomavirus Infection .................................................................. 84 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 25 Anogenital Warts ................................................................................................ 86 Chancroid .......................................................................................................... 26 HPV-Associated Cancers and Precancers ................................................... 90 Genital HSV Infections .................................................................................. 27 Viral Hepatitis ....................................................................................................... 94 Granuloma Inguinale (Donovanosis) ....................................................... 32 Hepatitis A ......................................................................................................... 94 Lymphogranuloma Venereum ................................................................... 33 Hepatitis B ......................................................................................................... 95 Syphilis ................................................................................................................... 34 Proctitis, Proctocolitis, and Enteritis ..........................................................100 Management of Persons Who Have a History of Penicillin Allergy .. 49 Ectoparasitic Infections ..................................................................................101 Diseases Characterized by Urethritis and Cervicitis ............................... 51 Pediculosis Pubis ...........................................................................................101 Urethritis ............................................................................................................ 51 Scabies ..............................................................................................................102 Nongonococcal Urethritis ............................................................................ 52 Sexual Assault and Abuse and STDs ..........................................................104 Cervicitis ............................................................................................................. 53 References ...........................................................................................................110 Chlamydial Infections ....................................................................................... 55 Terms and Abbreviations Used in This Report .......................................135 The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027. Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR Recomm Rep 2015;64(No. RR-#):[inclusive page numbers]. Centers for Disease Control and Prevention Thomas R. Frieden, MD, MPH, Director Harold W. Jaffe, MD, MA, Associate Director for Science Joanne Cono, MD, ScM, Director, Office of Science Quality Chesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services MMWR Editorial and Production Staff (Serials) Sonja A. Rasmussen, MD, MS, Editor-in-Chief Martha F. Boyd, Lead Visual Information Specialist Charlotte K. Kent, PhD, MPH, Executive Editor Maureen A. Leahy, Julia C. Martinroe, Christine G. Casey, MD, Editor Stephen R. Spriggs, Visual Information Specialists Teresa F. Rutledge, Managing Editor Quang M. Doan, MBA, Phyllis H. King David C. Johnson, Lead Technical Writer-Editor Terraye M. Starr, Information Technology Specialists Rachel J. Wilson, Project Editor MMWR Editorial Board William L. Roper, MD, MPH, Chapel Hill, NC, Chairman King K. Holmes, MD, PhD, Seattle, WA Matthew L. Boulton, MD, MPH, Ann Arbor, MI Timothy F. Jones, MD, Nashville, TN Virginia A. Caine, MD, Indianapolis, IN Rima F. Khabbaz, MD, Atlanta, GA Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA Patricia Quinlisk, MD, MPH, Des Moines, IA David W. Fleming, MD, Seattle, WA Patrick L. Remington, MD, MPH, Madison, WI William E. Halperin, MD, DrPH, MPH, Newark, NJ William Schaffner, MD, Nashville, TN Recommendations and Reports Sexually Transmitted Diseases Treatment Guidelines, 2015 Prepared by Kimberly A. Workowski, MD1,2 Gail A. Bolan, MD1 1Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 2Emory University, Atlanta, Georgia Summary These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30–May 2, 2013. The information in this report updates the Sexually Transmitted Diseases Treatment Guidelines, 2010 (MMWR Recomm Rep 2010;59 [No. RR–12]). These updated guidelines discuss 1) alternative treatment regimens for Neisseria gonorrhoeae; 2) the use of nucleic acid amplification tests for the diagnosis of trichomoniasis; 3) alternative treatment options for genital warts; 4) the role of Mycoplasma genitalium in urethritis/cervicitis and treatment-related implications; 5) updated HPV vaccine recommendations and counseling messages; 6) the management of persons who are transgender; 7) annual testing for hepatitis C in persons with HIV infection; 8) updated recommendations for diagnostic evaluation of urethritis; and 9) retesting to detect repeat infection. Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STDs. Introduction on the basis of their expertise in the clinical management of STDs. Members of the multidisciplinary workgroup included The term sexually transmitted diseases (STDs) refers to representatives from federal, state, and local health departments; a variety of clinical syndromes and infections caused by public- and private-sector clinical providers; clinical and basic pathogens that can be acquired and transmitted through sexual science researchers; and numerous professional organizations. activity. Physicians and other health-care providers play a All workgroup members disclosed potential conflicts of interest; critical role in preventing and treating STDs. These guidelines several members of the workgroup acknowledged receiving for the treatment of STDs are intended to assist with that effort. financial support for clinical research from commercial Although these guidelines emphasize treatment, prevention companies. All potential conflicts of interest are listed at the strategies and diagnostic recommendations also are discussed. end of the workgroup member section. Sexually Transmitted Diseases This document updates CDC’s In 2012, CDC staff and workgroup members were charged Treatment Guidelines, 2010 1 ( ). These recommendations should with identifying key questions regarding treatment and be regarded as a source of clinical guidance rather than prescriptive clinical management that were not addressed in the 2010 standards; health-care providers should always consider the STD Treatment Guidelines (1). To answer these questions clinical circumstances of each person in the context of local disease and synthesize new information available since publication of prevalence. These guidelines are applicable
Recommended publications
  • Vaccine to Prevent Human Papillomavirus
    Resolution No. 6/20-1 ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT MENINGOCOCCAL DISEASE The purpose of this resolution is to update the resolution to reflect currently available meningococcal conjugate vaccines that can be used to prevent meningococcal disease attributable to serogroups A, C, W, and Y. VFC resolution 6/19-7 is repealed and replaced by the following: Meningococcal Conjugate Vaccines (MenACWY) Eligible Groups • Children aged 2 months through 10 years who are at increased risk for meningococcal disease attributable to serogroups A, C, W, and Y, including: o Children who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D) o Children taking a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris]) o Children who have anatomic or functional asplenia, including sickle cell disease o Children infected with human immunodeficiency virus (HIV) o Children traveling to or residing in countries in which meningococcal disease is hyperendemic or epidemic, particularly if contact with local population will be prolonged o Children identified to be at increased risk because of a meningococcal disease outbreak attributable to serogroups A, C, W, or Y • All children aged 11 through 18 years 1 Recommended Vaccination Schedule and Intervals The table below lists meningococcal conjugate vaccines currently available to prevent meningococcal disease attributable to serogroups A, C, W, and
    [Show full text]
  • An Atlas of Potentially Water-Related Diseases in South Africa
    AN ATLAS OF POTENTIALLY WATER-RELATED DISEASES IN SOUTH AFRICA Volume 2 Bibliography Report to the WATER RESEARCH COMMISSION by N Coetzee and D E Bourne Department of Community Health University of Cape Town Medical School WRC Report no. 584/2/96 ISBN 1 86845 245 X ISBN Set No 1 86845 246 8 1 CONTENTS VOLUME 2 BIBLIOGRAPHY 1 Introduction 2 2 Amoebiasis 3 3 Arthropod-borne viral diseases 7 4 Cholera 10 5 Diarrhoeal diseases in childhood 14 6 Viral hepatitis A and E 17 7 Leptospirosis 20 3 Pediculosis 22 9 Malaria 23 10 Poliomyelitis 29 11 Scabies 33 12 Schistosomiasis 35 13 Trachoma 39 14 Typhoid Fever 42 15 Intestinal helminthiasis 46 1. INTRODUCTION As many professionals involved in the management of water resources do not have a medical or public health background, it was thought that an explanatory bibliography of the major water related diseases in South Africa would be of use. Each section of the bibliography has (where appropriate) the following sections: 1. Aetiology 2. Transmission 3. Preventive and curative steps 4. South African data 5. References The MEDLINE data base of the national Library of Medicine, Washington DC, and the WATERLIT data base of the CSIR were searched. These were supplemented by South African journals and reports not appearing in the MEDLINE data base. 3 2. AMOEBIASIS 2.1. Aetiology The protozoan parasite Entamoeba histolytica which causes amoebiasis may exist as a hardy infective cyst or a more fragile and potentially pathogenic trophozoite (the "amoebic" form). Amoebiasis most commonly affects the colon and rectum as primary sitas of infection, with extraintestinal (most commonly liver abscesses), local or systemic, spread possible if not treated early.
    [Show full text]
  • Infectious Disease
    INFECTIOUS DISEASE Infectious diseases are caused by germs that are transmitted directly from person to NOTE: person; animal to person (zoonotic The following symbols are used throughout this Community Health Assessment Report to serve only as a simple and quick diseases); from mother to unborn child; or reference for data comparisons and trends for the County. indirectly, such as when a person touches Further analysis may be required before drawing conclusions about the data. a surface that some germs can linger on. The NYSDOH recommends several The apple symbol represents areas in which Oneida County’s status or trend is FAVORABLE or COMPARABLE to its effective strategies for preventing comparison (i.e., NYS, US) or areas/issues identified as infectious diseases,, including: ensuring STRENGTHS. procedures and systems are in place in The magnifying glass symbols represent areas in which Oneida County’s status or trend is UNFAVORABLE to its communities for immunizations to be up to comparison (i.e., NYS, US) or areas/issues of CONCERN date; enabling sanitary practices by or NEED that may warrant further analysis. conveniently located sinks for washing DATA REFERENCES: hands; influencing community resources • All References to tables are in Attachment A – Oneida County Data Book. and cultures to facilitate abstinence and • See also Attachment B – Oneida County Chart Book for risk reduction practices for sexual behavior additional data. and injection drug use, and setting up support systems to ensure medicines are taken as prescribed.453 The reporting of suspect or confirmed communicable diseases is mandated under the New York State Sanitary Code (10NYCRR 2.10).
    [Show full text]
  • Dyspareunia: an Integrated Approach to Assessment and Diagnosis
    PROBLEMS IN FAMILY PRACTICE Dyspareunia: An Integrated Approach to Assessment and Diagnosis Genell Sandberg, PhD, and Randal P. Quevillon, PhD Seattle, Washington, and Vermillion, South Dakota Dyspareunia, or painful intercourse, is frequently referred to as the most common female sexual dysfunction. It can occur singly or be manifested in combination with other psychosexual disorders. Diagnosis of dyspareunia is appropriate in cases in which the experience of pain is persistent and severe. There has been little agreement concerning the origin of dyspareunia. Or­ ganic conditions and psychological variables have alternately been pre­ sented as major factors in causality. There is a presumed high incidence of physical disease associated with dyspareunia when compared with other female sexual dysfunctions. In the majority of cases, however, organic fac­ tors are thought to be rare in contrast with sexual issues and interpersonal or intrapsychic difficulties as a cause of continuing problems. The finding of an organic basis for dyspareunia does not rule out emotional or psychogenic causes. Thorough and extensive gynecologic and psycholog­ ical evaluation is essential in cases of dyspareunia. The etiology of dys­ pareunia should be viewed on a continuum from primarily physical to primar­ ily psychological with many women falling in the middle area. recurrent pattern of genital pain during or im­ Dyspareunia and vaginismus are undeniably linked, A mediately after coitus is the basis for the diagnosis and repeated dyspareunia is likely to result in vaginis­ of dyspareunia.1 The Diagnostic and Statistical Man­ mus, as vaginismus may be the causative factor in ual of Mental Disorders (DSM-III)2 has included dys­ dyspareunia.6-7 The difference between vaginismus pareunia under the classification of psychosexual dis­ and dyspareunia is that intromission is generally pain­ orders.
    [Show full text]
  • Parinaud's Oculoglandular Syndrome
    Tropical Medicine and Infectious Disease Case Report Parinaud’s Oculoglandular Syndrome: A Case in an Adult with Flea-Borne Typhus and a Review M. Kevin Dixon 1, Christopher L. Dayton 2 and Gregory M. Anstead 3,4,* 1 Baylor Scott & White Clinic, 800 Scott & White Drive, College Station, TX 77845, USA; [email protected] 2 Division of Critical Care, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; [email protected] 3 Medical Service, South Texas Veterans Health Care System, San Antonio, TX 78229, USA 4 Division of Infectious Diseases, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA * Correspondence: [email protected]; Tel.: +1-210-567-4666; Fax: +1-210-567-4670 Received: 7 June 2020; Accepted: 24 July 2020; Published: 29 July 2020 Abstract: Parinaud’s oculoglandular syndrome (POGS) is defined as unilateral granulomatous conjunctivitis and facial lymphadenopathy. The aims of the current study are to describe a case of POGS with uveitis due to flea-borne typhus (FBT) and to present a diagnostic and therapeutic approach to POGS. The patient, a 38-year old man, presented with persistent unilateral eye pain, fever, rash, preauricular and submandibular lymphadenopathy, and laboratory findings of FBT: hyponatremia, elevated transaminase and lactate dehydrogenase levels, thrombocytopenia, and hypoalbuminemia. His condition rapidly improved after starting doxycycline. Soon after hospitalization, he was diagnosed with uveitis, which responded to topical prednisolone. To derive a diagnostic and empiric therapeutic approach to POGS, we reviewed the cases of POGS from its various causes since 1976 to discern epidemiologic clues and determine successful diagnostic techniques and therapies; we found multiple cases due to cat scratch disease (CSD; due to Bartonella henselae) (twelve), tularemia (ten), sporotrichosis (three), Rickettsia conorii (three), R.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Pelvic Inflammatory Disease (PID) PELVIC INFLAMMATORY DISEASE (PID)
    Clinical Prevention Services Provincial STI Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel : 604.707.5600 Fax: 604.707.5604 www.bccdc.ca BCCDC Non-certified Practice Decision Support Tool Pelvic Inflammatory Disease (PID) PELVIC INFLAMMATORY DISEASE (PID) SCOPE RNs (including certified practice RNs) must refer to a physician (MD) or nurse practitioner (NP) for all clients who present with suspected PID as defined by pelvic tenderness and lower abdominal pain during the bimanual exam. ETIOLOGY Pelvic inflammatory disease (PID) is an infection of the upper genital tract that involves any combination of the uterus, endometrium, ovaries, fallopian tubes, pelvic peritoneum and adjacent tissues. PID consists of ascending infection from the lower-to-upper genital tract. Prompt diagnosis and treatment is essential to prevent long-term sequelae. Most cases of PID can be categorized as sexually transmitted and are associated with more than one organism or condition, including: Bacterial: Chlamydia trachomatis (CT) Neisseria gonorrhoeae (GC) Trichomonas vaginalis Mycoplasma genitalium bacterial vaginosis (BV)-related organisms (e.g., G. vaginalis) enteric bacteria (e.g., E. coli) (rare; more common in post-menopausal people) PID may be associated with no specific identifiable pathogen. EPIDEMIOLOGY PID is a significant public health problem. Up to 2/3 of cases go unrecognized, and under reporting is common. There are approximately 100,000 cases of symptomatic PID annually in Canada; however, PID is not a reportable infection so, exact
    [Show full text]
  • Nutrition in Andrology, Gynaecology and Obstetrics
    Appendix No. 2 to the procedure of development and periodical review of syllabuses Nutrition in Andrology, Gynaecology and Obstetrics 1. Imprint Faculty name: English Division Syllabus (field of study, level and educational profile, form of studies, Medicine, 1st level studies, practical profile, full time e.g., Public Health, 1st level studies, practical profile, full time): Academic year: 2019/2020 Nutrition in Andrology, Gynaecology and Module/subject name: Obstetrics Subject code (from the Pensum system): Educational units: Department of Social Medicine and Public Health Head of the unit/s: Dr hab. n. med. Aneta Nitsch - Osuch Study year (the year during which the 1st-6th respective subject is taught): Study semester (the semester during which the respective subject is Winter and Summer semesters taught): Module/subject type (basic, corresponding to the field of study, Optional optional): Teachers (names and surnames and Anna Jagielska, MD degrees of all academic teachers of Aleksandra Kozłowska, BSc respective subjects): ERASMUS YES/NO (Is the subject available for students under the YES ERASMUS programme?): A person responsible for the syllabus (a person to which all comments to Anna Jagielska, MD the syllabus should be reported) Number of ECTS credits: 2 Page 1 of 4 Appendix No. 2 to the procedure of development and periodical review of syllabuses 2. Educational goals and aims The aim of the course is to provide students with: 1. The principles of nutrition during adolescence, adulthood and eldery. 2. The relationship between nutrition and fertility, fetal status and communicable diseases in the adults life. 3. Basics of dietary advices for men and women in the reproductive years.
    [Show full text]
  • Kellie ID Emergencies.Pptx
    4/24/11 ID Alert! recognizing rapidly fatal infections Susan M. Kellie, MD, MPH Professor of Medicine Division of Infectious Diseases, UNMSOM Hospital Epidemiologist UNMHSC and NMVAHCS Fever and…. Rash and altered mental status Rash Muscle pain Lymphadenopathy Hypotension Shortness of breath Recent travel Abdominal pain and diarrhea Case 1. The cross-country trucker A 30 year-old trucker driving from Oklahoma to California is hospitalized in Deming with fever and headache He is treated with broad-spectrum antibiotics, but deteriorates with obtundation, low platelet count, and a centrifugal petechial rash and is transferred to UNMH 1 4/24/11 What is your diagnosis? What is the differential diagnosis of fever and headache with petechial rash? (in the US) Tickborne rickettsioses ◦ RMSF Bacteria ◦ Neisseria meningitidis Key diagnosis in this case: “doxycycline deficiency” Key vector-borne rickettsioses treated with doxycycline: RMSF-case-fatality 5-10% ◦ Fever, nausea, vomiting, myalgia, anorexia and headache ◦ Maculopapular rash progresses to petechial after 2-4 days of fever ◦ Occasionally without rash Human granulocytotropic anaplasmosis (HGA): case-fatality<1% Human monocytotropic ehrlichiosis (HME): case fatality 2-3% 2 4/24/11 Lab clues in rickettsioses The total white blood cell (WBC) count is typicallynormal in patients with RMSF, but increased numbers of immature bands are generally observed. Thrombocytopenia, mild elevations in hepatic transaminases, and hyponatremia might be observed with RMSF whereas leukopenia
    [Show full text]
  • Scuba Diving History
    Scuba diving history Scuba history from a diving bell developed by Guglielmo de Loreno in 1535 up to John Bennett’s dive in the Philippines to amazing 308 meter in 2001 and much more… Humans have been diving since man was required to collect food from the sea. The need for air and protection under water was obvious. Let us find out how mankind conquered the sea in the quest to discover the beauty of the under water world. 1535 – A diving bell was developed by Guglielmo de Loreno. 1650 – Guericke developed the first air pump. 1667 – Robert Boyle observes the decompression sickness or “the bends”. After decompression of a snake he noticed gas bubbles in the eyes of a snake. 1691 – Another diving bell a weighted barrels, connected with an air pipe to the surface, was patented by Edmund Halley. 1715 – John Lethbridge built an underwater cylinder that was supplied via an air pipe from the surface with compressed air. To prevent the water from entering the cylinder, greased leather connections were integrated at the cylinder for the operators arms. 1776 – The first submarine was used for a military attack. 1826 – Charles Anthony and John Deane patented a helmet for fire fighters. This helmet was used for diving too. This first version was not fitted to the diving suit. The helmet was attached to the body of the diver with straps and air was supplied from the surfa 1837 – Augustus Siebe sealed the diving helmet of the Deane brothers’ to a watertight diving suit and became the standard for many dive expeditions.
    [Show full text]
  • Chlamydia-English
    URGENT and PRIVATE IMPORTANT INFORMATION ABOUT YOUR HEALTH DIRECTIONS FOR SEX PARTNERS OF PERSONS WITH CHLAMYDIA PLEASE READ THIS VERY CAREFULLY Your sex partner has recently been treated for chlamydia. Chlamydia is a sexually transmitted disease (STD) that you can get from having any kind of sex (oral, vaginal, or anal) with a person who already has it. You may have been exposed. The good news is that it’s easily treated. You are being given a medicine called azithromycin (sometimes known as “Zithromax”) to treat your chlamydia. Your partner may have given you the actual medicine, or a prescription that you can take to a pharmacy. These are instructions for how to take azithromycin. The best way to take care of this infection is to see your own doctor or clinic provider right away. If you can’t get to a doctor in the next several days, you should take the azithromycin. Even if you decide to take the medicine, it is very important to see a doctor as soon as you can, to get tested for other STDs. People can have more than one STD at the same time. Azithromycin will not cure other sexually transmitted infections. Having STDs can increase your risk of getting HIV, so make sure to also get an HIV test. SYMPTOMS Some people with chlamydia have symptoms, but most do not. Symptoms may include pain in your testicles, pelvis, or lower part of your belly. You may also have pain when you urinate or when having sex. Many people with chlamydia do not know they are infected because they feel fine.
    [Show full text]
  • Figure 1: Etest Gradient Configuration When an Etest Gradient Strip Is
    Inoculum preparation Table 1. Recommended media, inoculum and To obtain reproducible MICs from a gradient based Use the inoculum guide in TABLE 1. Emulsify several incubation1). system, the stability of the gradient must be maintai- well-isolated colonies from an overnight agar plate in lêÖ~åáëã= ^Ö~ê= fåçÅìäìã fåÅìÄ~íáçå ned throughout the critical period when the position a suitable suspension medium to achieve the specifi ed Öêçìé ãÉÇá~ of the growth/inhibition edge for a particular bac- inoculum turbidity by comparing to a McFarland pìëéÉåëáçå qìêÄáÇáíó= qÉãéÉê~íìêÉ= ^íãçëéÜÉêÉ qáãÉ= Antimicrobial Susceptibility Testing terium/antibiotic combination is determined. Due turbidity standard. For fastidious organisms such as EjÅc~êä~åÇF Eœ=O=ø`F EÜçìêëF For In Vitro Diagnostic Use to the stability and precision of the Etest predefi ned pneumococci, streptococci, gonococci, anaerobes and gradient, MIC values have been shown to be repro- Haemophilus spp., use the suspension prepared in INTENDED USE ducible and equivalent to those of the CLSI reference broth within 15 minutes. ^ÉêçÄÉë jìÉääÉê= MKURB=k~`ä MKR================== PR=ø` ~ãÄáÉåí NSJOM Etest is a quantitative technique for determining dilution procedures. eáåíçå EN=áÑ=ãìÅçáÇF the antimicrobial susceptibility of Gram negative Inoculation and Gram positive aerobic bacteria such as En- REAGENTS Soak a sterile, non-toxic swab in the inoculum terobacteriaceae, Pseudomonas, Staphylococcus and Etest is supplied in a package of 100 or 30 (some suspension and remove excess fl uid by pressing it lop^L=lopb jìÉääÉê= MKURB=k~`ä MKR PR=ø` ~ãÄáÉåí OQ=lop^==== Enterococcus species and fastidious bacteria, such as reagents) test strips of one antimicrobial agent.
    [Show full text]